Form 4: Ardelyx Officer Sells Shares for Tax Withholding

Ardelyx's Chief Patient Officer, Laura A. Williams, sold 6,261 shares of common stock to cover tax obligations upon the vesting of restricted stock units.

Summary

• Laura A. Williams, Chief Patient Officer of ARDELYX, INC. (ARDX), reported a transaction on August 21, 2025.
• The transaction involved the disposition of 6,261 shares of ARDELYX Common Stock.
• The shares were sold at a price of $5.9317 per share.
• This sale was an automatic 'sell-to-cover' transaction, executed upon the vesting of restricted stock units (RSUs), solely to cover applicable withholding taxes.
• Following this transaction, Laura A. Williams beneficially owns 396,322 shares of ARDELYX Common Stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell-to-cover' for tax purposes upon RSU vesting, indicating no change in management's sentiment towards the company or its future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The shares were sold pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ('RSUs') awards, solely to cover applicable withholding taxes.

Industry Context

This type of 'sell-to-cover' transaction is a common and routine event in executive compensation, particularly when restricted stock units vest. It does not typically reflect a discretionary investment decision by the executive but rather a mechanism to satisfy tax obligations arising from compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the executive's confidence in the company.

Key Dates

Recommendation

The transaction is a standard 'sell-to-cover' to satisfy tax obligations upon the vesting of restricted stock units, not a discretionary sale reflecting a change in the officer's view of the company's prospects. Therefore, it does not provide new information to alter an existing investment thesis or warrant a change in recommendation.

Keywords

Ardelyx, ARDX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Laura A. Williams, Chief Patient Officer